natgillin/translations-raw huggingface dataset:
14 prolonged-release tablets - EU/1/07/395/069 - WHITE 28 prolonged-release tablets - EU/1/07/395/026 - WHITE 30 prolonged-release tablets - EU/1/07/395/027 - WHITE 49 prolonged-release tablets - EU/1/07/395/028 - WHITE 56 prolonged-release tablets - EU/1/07/395/029 - WHITE 98 prolonged-release tablets - EU/1/07/395/030 - WHITE
14 tableta s produljenim oslobađanjem - EU/1/07/395/069 - BIJELI 28 tableta s produljenim oslobađanjem - EU/1/07/395/026 - BIJELI 30 tableta s produljenim oslobađanjem - EU/1/07/395/027 - BIJELI 49 tableta s produljenim oslobađanjem - EU/1/07/395/028 - BIJELI 56 tableta s produljenim oslobađanjem - EU/1/07/395/029 - BIJELI 98 tableta s produljenim oslobađanjem - EU/1/07/395/030 - BIJELI
14 prolonged-release tablets - EU/1/07/395/077 - CLEAR 28 prolonged-release tablets - EU/1/07/395/078 - CLEAR 30 prolonged-release tablets - EU/1/07/395/079 - CLEAR 49 prolonged-release tablets - EU/1/07/395/080 - CLEAR 56 prolonged-release tablets - EU/1/07/395/081 - CLEAR 98 prolonged-release tablets - EU/1/07/395/082 – CLEAR
14 tableta s produljenim oslobađanjem - EU/1/07/395/077 - PROZIRNI 28 tableta s produljenim oslobađanjem - EU/1/07/395/078 - PROZIRNI 30 tableta s produljenim oslobađanjem - EU/1/07/395/079 - PROZIRNI 49 tableta s produljenim oslobađanjem - EU/1/07/395/080 - PROZIRNI 56 tableta s produljenim oslobađanjem - EU/1/07/395/081 - PROZIRNI 98 tableta s produljenim oslobađanjem - EU/1/07/395/082 - PROZIRNI
14 prolonged-release tablets - EU/1/07/395/083 - WHITE 28 prolonged-release tablets - EU/1/07/395/084 - WHITE 30 prolonged-release tablets - EU/1/07/395/085 - WHITE 49 prolonged-release tablets - EU/1/07/395/086 - WHITE 56 prolonged-release tablets - EU/1/07/395/087 - WHITE 98 prolonged-release tablets - EU/1/07/395/088 - WHITE
14 tableta s produljenim oslobađanjem - EU/1/07/395/083 - BIJELI 28 tableta s produljenim oslobađanjem - EU/1/07/395/084 - BIJELI 30 tableta s produljenim oslobađanjem - EU/1/07/395/085 - BIJELI 49 tableta s produljenim oslobađanjem - EU/1/07/395/086 - BIJELI 56 tableta s produljenim oslobađanjem - EU/1/07/395/087 - BIJELI 98 tableta s produljenim oslobađanjem - EU/1/07/395/088 - BIJELI
14 prolonged-release tablets - EU/1/07/395/089 28 prolonged-release tablets - EU/1/07/395/090 49 prolonged-release tablets - EU/1/07/395/091 56 prolonged-release tablets - EU/1/07/395/092 98 prolonged-release tablets - EU/1/07/395/093
14 tableta s produljenim oslobađanjem - EU/1/07/395/089 28 tableta s produljenim oslobađanjem - EU/1/07/395/090 49 tableta s produljenim oslobađanjem - EU/1/07/395/091 56 tableta s produljenim oslobađanjem - EU/1/07/395/092 98 tableta s produljenim oslobađanjem - EU/1/07/395/093
14 rue de la Grange aux Belles 75010 Paris
14 rue de la Grange aux Belles 75010 Pariz
14 rue Gustave Eiffel 10430 Rosières près Troyes France
14 rue Gustave Eiffel 10430 Rosières près Troyes Francuska
14 tablets
14 tablete
14 tablets
EU/1/13/891/033
14 tablets (PA/Alu/PVC blisters)
14 tableta (PA/Al/PVC blisteri)
14 tablets (PVC/PCTFE blisters)
14 tableta (PVC/PCTFE blisteri)
14 tablets blister: Mon.
Blister s 14 tableta: Pon.
14 tablets: EU/1/08/480/001
14 tableta: EU/1/08/480/001
14 tablets: EU/1/08/480/007
14 tableta: EU/1/08/480/007
14 tablets: EU/1/08/480/013
14 tableta: EU/1/08/480/013
14 tablets: EU/1/10/632/001
14 tableta: EU/1/10/632/001
14 tablets: EU/1/10/632/008
14 tableta: EU/1/10/632/008
14 tablets: EU/1/10/632/015
14 tableta: EU/1/10/632/015
14 tablets: EU/1/11/721/001
14 tableta: EU/1/11/721/001
14 tablets: EU/1/11/721/008
14 tableta: EU/1/11/721/008
14 tablets: EU/1/11/721/015
14 tableta: EU/1/11/721/015
14 tablets: EU/1/11/723/001
14 tableta: EU/1/11/723/001
14 tablets: EU/1/11/723/008
14 tableta: EU/1/11/723/008
14 tablets: EU/1/11/723/015
14 tableta: EU/1/11/723/015
14 to < 17
14 do < 17
14 to less than 20†
od 14 do manje od 20
14 vials + 15 pre-filled syringes (luer lock)
bočica + napunjenih štrcaljki (luer zatvarač)
14 vials of interferon beta-1b and 14 pre-filled syringes containing solvent.
14 bočica interferona beta-1b i 14 napunjenih štrcaljki koje sadrže otapalo.
14 x 1 capsules (unit
14 x 1 kapsula
14 x 1 capsules (unit
14 x 1 kapsula (jedinična doza)
14 x 1 capsules (unit dose)
14 x 1 kapsula (jedinična doza)
14 x 1 film-coated tablet
14 x 1 filmom obložena tableta
14 x 1 film-coated tablets
14 x 1 filmom obložena tableta
14 x 1 film-coated tablets
14 x 1 filmom obloženih tableta
14 x 1 hard capsules
14 x 1 tvrda kapsula
14 x 1 tablet
14 x 1 tableta
14 x 1 tablet (unit dose)
14 x 1 tableta (jedinična doza)
14 x 1 tablets
14 x 1 tableta
14 x 1 tablets (unit dose)
14 x 1 tableta (jedinična doza)
14 x1 capsules (unit dose)
14 x1 kapsula (jedinična doza)
14, 28 and 84 tablets in all-aluminium blisters
14, 28 i 84 tablete u aluminijskim blisterima
14, 28, 30 and 84 tablets in all-aluminium blisters
14, 28, 30 i 84 tablete u aluminijskim blisterima
14, 28, 84 and 98 tablets in wallet packs with integrated aluminium blisters;
14, 28, 84 i 98 tableta u kartonskim ovicima s integriranim aluminijskim blisterima;
14, rue de la Grange aux Belles 75010 Paris
14, rue de la Grange aux Belles 75010 Pariz
14-hydroxymetabolite: AUC: ↑ 34% (↑ 18 to ↑ 53)
AUC: ↑ 34% (↑ 18 do ↑ 53)
14-OH clarithromycin AUC
14-OH klaritromicin AUC ↓70
14-OH clarithromycin AUC ↓70%
14-OH klaritromicin AUC ↓70
14-OH clarithromycin Cmax ↓72%
14-OH klaritromicin Cmax ↓72
14-OH clarithromycin Cmin ↓62%
14-OH klaritromicin Cmin ↓62
14-OH clarithromycin Cmin ↓62%
14-OH klaritromicin Cmin ↓62% (↓66
14-OH-clarithromycin AUC ↑ 1.21 (1.05-1.39)
14-OH-klaritromicin AUC ↑ 1,21 (1,05-1,39)
14-OH-clarithromycin concentrations were not detectable when combined with PREZISTA/ritonavir.
Koncentraciju 14-OH- klaritromicina
14.0 mo (11.1, 15.0)
14,0 mjeseci (11,1, 15,0)
14.1 l/hr, respectively).
Inhibicija CYP1A2:
14.1 l/hr, respectively).
Toskičnost ponavljane doze
14.1 mg/dl to 12.4 mg/dl (3.5 mmol/l to 3.1 mmol/l), while in patients with primary HPT, serum calcium levels declined from 12.7 mg/dl to 10.4 mg/dl (3.2 mmol/l to 2.6 mmol/l).
3,1 mmol/l), a u bolesnika s primarnim HPT-om vrijednost serumskog kalcija smanjila se s 12,7 mg/dl na 10,4 mg/dl (3,2 mmol/l na 2,6 mmol).
14.2 ml Type I or Type III amber bottle (glass) fitted with a metering spray pump.
14,2 ml u smeđoj (staklenoj) bočici tipa I ili tipa III s odmjernom pumpicom raspršivača.
14.5 months respectively) with a 28% risk reduction of mortality, p = 0.0128. Efficacy results are presented in the table below:
Rezultati djelotvornosti prikazani su u donjoj tablici:
14.56 (2.19, 26.94)
Klinička remisija prema indeksu SDAIb
14.6 months (11.1, 17.5)
14,6 mjeseci (11,1, 17,5)
14.6L/min p<0.001 (7.9, 21.3)
14,6 l/min p<0,001 (7,9; 21,3)
14.8 (14.1; 15.4) 10.9 (10.2; 12.0) p-valuea < 0.0001
14,8 (14,1; 15,4) 10,9 (10,2; 12,0)
14.9 (10.4, NA)
14,9 (10,4; ND)
14.GENERAL CLASSIFICATION FOR SUPPLY
NAČIN IZDAVANJA LIJEKA
14.Remain seated or lying down for 20 minutes after injecting Ceplene.
Ostanite sjediti ili ležati 20 minuta nakon ubrizgavanja Ceplenea.
140 capsules
140 kapsula
140 capsules
EU/1/04/280/005
140 film-coated tablets
140 filmom obloženih tableta
140 film-coated tablets Titration pack
140 filmom obloženih tableta Pakiranje za titraciju doze
140 hard capsules
140 tvrdih kapsula
140 mg (1 orange 80 mg capsule and 3 grey 20 mg capsules)
140 mg (1 narančasta kapsula od 80 mg i 3 sive kapsule od 20 mg)
140 mg once daily  n = 304 All grades Grade 3/4
140 mg jedanput dnevno  n = 304 Svi stupnjevi 3./4. stupanj
140 tablets
140 tableta
140 tablets (titration pack)
140 tableta (pakiranje za titraciju)
140mg/7 ml contains 7 ml of concentrate.
140mg/7 ml sadrži 7 ml koncentrata.
141 days
141 dana
1411DD Naarden The Netherlands
1411DD Naarden Nizozemska
14129 Berlin Germany
14129 Berlin Njemačka
144 tablets
144 tablete
144 weeks
144 tjedna
145 mg/36.25 mg modified-release hard capsule
Tvrde kapsule s prilagođenim oslobađanjem od 145 mg/36,25 mg
145 mg/36.25 mg modified-release hard capsules
Tvrde kapsule s prilagođenim oslobađanjem od 145 mg/36,25 mg
146 mg sacubitril/154 mg valsartan/kg/day for 39 weeks, there was no evidence for the presence of amyloid plaques in the brain.
146 mg sakubitrila/154 mg valsartana/kg/dan tijekom 39 tjedana, nije bilo dokaza prisutnosti amiloidnih plakova u mozgu.
146 patients randomised to Simponi 50 mg, 70 were still on this treatment at week 104.
Od 146 bolesnika randomiziranih u skupinu koja je primala Simponi 50 mg, 70 ih je i dalje uzimalo tu terapiju u 104. tjednu.
147 mg (1.5 ml) twice daily
147 mg (1,5 ml) dva puta na dan
149 patients in the Picato group and 140 in the vehicle group were followed for 12 months.
149 bolesnika u skupini lijeka Picato i 140 u skupini podloge praćeno je tijekom 12 mjeseci.
14x1 film-coated tablet 28x1 film-coated tablet 30x1 film-coated tablet 50x1 film-coated tablet 84x1 film-coated tablet 90x1 film-coated tablet 100x1 film-coated tablet
14x1 filmom obloženih tableta 28x1 filmom obloženih tableta 30x1 filmom obloženih tableta 50x1 filmom obloženih tableta 84x1 filmom obloženih tableta 90x1 filmom obloženih tableta 100x1 filmom obloženih tableta
14x1 film-coated tablets
14x1 filmom obloženih tableta
14x1 film-coated tablets 28x1 film-coated tablets 30x1 film-coated tablets 50x1 film-coated tablets 84x1 film-coated tablets 90x1 film-coated tablets 100x1 film-coated tablets
14 x1 filmom obloženih tableta 28 x1 filmom obloženih tableta 30 x1 filmom obloženih tableta 50 x1 filmom obloženih tableta 84 x1 filmom obložene tablete 90 x1 filmom obloženih tableta 100 x1 filmom obloženih tableta
14x1 film-coated tablets 28x1 film-coated tablets 30x1 film-coated tablets 50x1 film-coated tablets 84x1 film-coated tablets 90x1 film-coated tablets 100x1 film-coated tablets
28 x1 filmom obloženih tableta 30 x1 filmom obloženih tableta 50 x1 filmom obloženih tableta 84 x1 filmom obložene tablete 90 x1 filmom obloženih tableta 100 x1 filmom obloženih tableta 14 x1 filmom obloženih tableta
14x1 tablets (unit dose)
14x1 tableta (jedinična doza)
14x1 tablets 28x1 tablets 30x1 tablets 40x1 tablets 56x1 tablets 60x1 tablets 84x1 tablets 90x1 tablets 98x1 tablets 100x1 tablets
14x1 tableta 28x1 tableta 30x1 tableta 40x1 tableta 56x1 tableta 40x1 tableta 84x1 tableta 90x1 tableta 98x1 tableta 100x1 tableta
14x1 tablets 28x1 tablets 30x1 tablets 40x1 tablets 56x1 tablets 60x1 tablets 84x1 tablets 90x1 tablets 98x1 tablets 100x1 tablets 28 tablets
14x1 tableta 28x1 tableta 30x1 tableta 40x1 tableta 56x1 tableta 60x1 tableta 84x1 tableta 90x1 tableta 98x1 tableta 100x1 tableta
15 (4.7)
zimice
15 - You are now ready to inject.
15 – Sad ste spremni za injiciranje.
15 applicator tips
15 vrhova aplikatora
15 applicators
15 aplikatora
15 days; Milk:
15 dana; mlijeko:
15 doses.
15 doza
15 g x 1 tube
15 g x 1 tuba
15 inhalers
15 inhalatora
15 kg to less than 20 kg
15 kg do manje od 20 kg
15 kg to less than 20 kg
od 15 kg do manje od 20 kg
15 kg up to 23 kg
15 kg do 23 kg
15 mg
Doza
15 mg (orange)
15 mg (narančas ta)
15 mg every other day
15 mg svaki drugi dan
15 mg every other day
15 mg svaki drugi dan3
15 mg film-coated tablets: Each film-coated tablet contains 1.42 mg lactose monohydrate.
Filmom obložene tablete od 15 mg: Jedna filmom obložena tableta sadrži 1,42 mg laktoze hidrata.
15 mg once daily on days 1-21, every 28 days
15 mg jednom dnevno od 1. do 21. dana, svakih 28 dana
15 mg per day).
15 mg na dan).
15 mg tablet
tableta od 15 mg
15 mg tablet: blue, triangular (major axis: 6.58 mm, minor axis: 6.20 mm), shallow-convex, debossed with “OTSUKA” and “15” on one side.
Tableta od 45 mg: plava, kvadratna (stranica 6,8 mm, dulja os 8,2 mm), blago konveksna, s utisnutim “OTSUKA” i “45” na jednoj strani.
15 mg tablets: Opadry Blue containing hypromellose (E464), titanium dioxide (E171), polyethylene glycol 6000, indigo carmine aluminium lake (E132), brilliant blue FCF aluminium lake (E133) and iron oxide black (E172)
15 mg tablete : Opadry Blue sadrže hipromeloze ( E464 ) , titan dioksid ( E171 ) , polietilen glikol 6000 , indigo karmina aluminija jezero ( E132 ) , briljantne plavo FCF aluminija jezero ( E133 ) i željezo-oksid crni ( E172 )
15 mg twice daily
15 mg dvaput na dan
15 mg/kg q 3 weeks
15 mg/kg svaka 3 tjedna
15 mg/kg/day as 2 divided doses (n = 17)
15 mg/kg na dan podijeljeno u 2 doze (n=17)
15 mg/kg/day as 2 divided doses (n = 17)
15 mg/kg/dan u 2 podijeljene doze
15 mg/kg/day as 2 divided doses (n = 17)
15 mg/kg/dan u 2 podijeljene doze (n = 17)
15 mg/kg/day in a pharmacokinetic and tolerability study.
2,5, 5, 10 i 15 mg/kg/dan u ispitivanju farmakokinetike i podnošljivosti.
15 mg/kg/day in the 13-week subcutaneous toxicity studies both in rats and dogs and at 10 mg/kg/day in the 26-week subcutaneous and intravenous toxicity studies both in rats and monkeys.
15 mg/kg/dan tijekom ispitivanja supkutane toksičnosti u štakora i pasa u trajanju od 13 tjedana, te pri dozi od 10 mg/kg/dan tijekom ispitivanja supkutane i intravenske toksičnosti u štakora i majmuna u trajanju od 26 tjedana.
15 mg: Round and yellow, marked with "A" over "641" on one side and "15" on the other.
15 mg: Okrugla i žuta s oznakom "A" iznad "641" na jednoj strani i "15" na drugoj.
15 micrograms HA**
15 mikrograma HA
15 micrograms HA** A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B) .....15 micrograms HA** B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type)...............................................15 micrograms HA**
A/Hong Kong/4801/2014 (H3N2) - sličan soj (A/Hong Kong/4801/2014, NYMC X-263B) ............................15 mikrograma HA** B/Brisbane/60/2008 - sličan soj (B/Brisbane/60/2008, divlji tip) .......................................................................15 mikrograma HA
15 micrograms HA** Per 0.1 ml dose
15 mikrograma HA** Po dozi od 0,1 ml
15 minutes and should be administered as a single intravenous solution in a separate infusion line.
15 minuta i mora se primijeniti kao jednokratna intravenska otopina kroz zasebnu infuzijsku liniju.
15 ml
Ambalaža
15 ml
odobrenja
15 ml (three 5 ml vials)
15 ml (tri bočice od 5 ml)
15 ml bottle and a 3ml oral dosing syringe
15 ml bočica i šprica za peroralno doziranje od 3 ml
15 ml bottle and a 3ml oral dosing syringe
15 ml bočica polipropilenska šprica za peroralno doziranje od 3 ml
15 ml clear glass Type I vial with a bromobutyl rubber stopper and a flip-off cap.
Prozirna staklena bočica od 15 ml (staklo tip I), s čepom od bromobutilne gume i s "flip-off" zatvaračem.
15 ml clear glass Type I vial with a bromobutyl rubber stopper and a flip-off cap.
Prozirna staklena bočica od 15 ml (staklo tip I), s čepom od bromobutilne gume i sa "flip-off" zatvaračem.
15 ml clear glass Type I vial with a bromobutyl rubber stopper and aluminium seal and a plastic flip- off cap containing 10 ml of concentrate for solution for infusion.
Prozirna staklena bočica od 15 ml (staklo tip I) s 10 ml koncentrata, za otopinu za infuziju, s bromobutilnim gumenim čepom i aluminijskim prstenom te plastičnim "flip off" zatvaračem.
15 ml colourless European Pharmacopoeia Type I drawn glass vial closed with Teflon-coated chlorobutyl/natural rubber stopper and aluminium flip-off overseal.
Bočica od bezbojnog stakla tipa I prema Europskoj farmakopeji, volumena 15 ml, zatvorena teflonom obloženim čepom od klorbutilne/prirodne gume i aluminijskim zaštitnim "flip-off " zatvaračem.
15 ml colourless glass vial with a bromobutyl rubber stopper and an aluminium crimp cap with plastic flip-off component.
Bezbojna staklena bočica od 15 ml s čepom od brombutilne gume, aluminijskim prstenom i plastičnim "flip-off" zatvaračem.
15 ml concentrate in a vial (type I glass) with a stopper (bromobutyl rubber) and a seal (aluminium) with a flip-off cap.
15 ml koncentrata u bočici (staklo tipa I) s čepom (od bromobutilne gume) i zatvaračem (od aluminija) s ‘flip-off’ kapicom.
15 ml in an amber glass bottle with dropper applicator (LD-polyethylene), and child-resistant screw cap (polypropylene).
15 ml u jantarnoj staklenoj boci sa zatvaračem s kapaljkom (LD-polietilen) i sigurnosnim zatvaračem za djecu s navojem (polipropilen).
15 ml solution/day) administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1).
15 ml otopine/dan) i primjenjuje se jedanput dnevno neovisno o obrocima u obliku monoterapije ili kombinirane terapije (vidjeti dio 5.1).
15 mL, colourless, type I glass vial, closed with chlorobutyl rubber stopper and aluminium crimped capsule (green) containing 5.02 mg of powder.
Bezbojna, staklena bočica tipa I od 15 ml, zatvorena čepom od klorbutilne gume i zaštitnim aluminijskim zatvaračem (zelene boje) koja sadrži 5,02 mg praška.
15 mL, colourless, type I glass vial, closed with chlorobutyl rubber stopper and crimped aluminium capsule (yellow) containing 2.82 mg of powder.
Bezbojna, staklena bočica tipa I od 15 ml, zatvorena čepom od klorbutilne gume i zaštitnim aluminijskim zatvaračem (žute boje) koja sadrži 2,82 mg praška.
15 patients were between the age of 6 to less than 18 years old and 6 patients were less than 6 years old (total of 393 exposures of NovoThirteen in paediatric subjects (less than 18 years old).
15 bolesnika bilo je u dobi od 6 do manje od 18 godina, a 6 bolesnika je bilo mlađe od 6 godina (ukupno 393 izlaganja lijeku NovoThirteen u pedijatrijskih ispitanika (mlađih od 18 godina).
15 pipettes
15 pipeta
15 pipettes
3 pipete
15 rue des Pyrénées 91090 Lisses France
15 rue des Pyrénées 91090 Lisses Francuska
15 tablets
15 tableta
15 tablets
18 tableta
15 to 20 kg
15 do 20 kg
15 to 71 M
od 15 do 71 M
15 to < 20
15 do <20
15 to <30
15 - <30
15 to less than 35 200 mg 100 mg at least 35 300 mg 100 mg
15 do manje od 35 200mg 100 mg najmanje 35 300 mg 100 mg
15 vials of interferon beta-1b and 15 pre-filled syringes containing solvent.
15 bočica interferona beta-1b i 15 napunjenih štrcaljki koje sadrže otapalo.
15 vials with powder and 15 pre-filled syringes with solvent.
15 bočica s praškom i 15 napunjenih štrcaljki s otapalom.
15 vials with powder and 15 pre-filled syringes with solvent:
15 bočica s praškom i 15 napunjenih štrcaljki s otapalom:
15 years follow-up is recommended for every patient treated.
Kod svakog liječenog bolesnika preporučuje se praćenje u trajanju od 15 godina.
15 yrs
15 godina
15 µg haemagglutinin per strain per 0.1 ml dose
15 µg hemaglutinina po soju po dozi od 0,1 ml
15% (4/27)
T12/PR48
15%; P = .0004
15%; P = 0,0004
15%§ (n = 158)
12% (n = 157) 27% (n = 158)
15, boulevard Charles de Gaulle - 92707 Colombes Cedex, France
15, boulevard Charles de Gaulle - 92707 Colombes Cedex, Francuska
15, boulevard Charles de Gaulle 92707 Colombes Cedex
15, boulevard Charles de Gaulle 92707 Colombes Cedex Francuska
15-30 minutes (ml/hr)
15-30 minuta (ml/sat)
15.0 mo (14.1, 17.9)
15,0 mjeseci (14,1, 17,9)
15.0 mo (14.1, 17.9)
15,0 mjeseci (14,1; 17,9)
15.4 wks (8.4, 16.9)
15,4 tjedana (8,4; 16,9)
15.4% (p=0.001)
15,4% (p=0,001)
15.5% had received prior radiotherapy and 28.4% prior chemotherapy.
15,5% bolesnika prethodno je primilo radioterapiju, a 28,4% kemoterapiju.
15.6 to 17.4
15,6 do 17,4
15.7% ; 1.3%
vi generalizirani toničko-klonički
15.8 %
Podtip HIV-1
15.9%
Karbamazepin
15.Dispose of the syringe in the puncture-proof container as instructed.
Štrcaljku prema uputama odložite u neprobojni spremnik.
15.INSTRUCTIONS ON USE
UPUTE ZA UPORABU
15/03/2012
15. ožujka 2012.
150 (25x6x1) capsules
150 (25x6x1) kapsula
150 (3 x 50) tablets (multipack)
150 (3 x 50) tableta
150 (3x50) capsules
150 (3x50) kapsula
150 and 200 mg)
(REYATAZ 150 i 200 mg)
150 daily 500 q12h, ↑ 4-fold
150 na dan 500 svakih 12h ↑ 4 puta
150 doses
150 doza
150 film-coated tablets
150 filmom obloženih tableta
150 IU (300 IU/mL) recombinant follicle-stimulating hormone (FSH) activity.
150 IU (300 IU/ml) aktivnosti rekombinantnog folikulostimulirajućeg hormona (FSH).
150 IU/kg 3x/week
150 IU/kg 3x/tjedan
150 IU/kg 3x/week or 450 IU/kg once weekly
150 IU/kg 3x/tjedno ili 450 IU/kg 1x/tjedno
150 kHz to 80 MHz
150 kHz do 80 MHz
150 mcg/0.3 ml
150 mcg/0,3 ml
150 mg (1.5 ml) twice daily
150 mg (1,5 ml) dva puta na dan
150 mg 3 times per week on set
rifabutina je 150 mg triput tjedno u
150 mg and 500 mg film-coated tablets
150 mg i 500 mg filmom obložene tablete
150 mg bid with monitoring.
150 mg dvaput na dan uz nadzor.
150 mg film-coated tablets Ibandronic acid
150 mg filmom obložene tablete ibandronatna kiselina
150 mg for patients with body weight > 40 kg
150 mg za bolesnike s tjelesnom težinom >40 kg
150 mg for patients with body weight more than 40 kg
150 mg za bolesnike tjelesne težine veće od 40 kg
150 mg once daily
150 mg jednom dnevno
150 mg once daily alone.
150 mg jedanput na dan.
150 mg once daily alone.
rifabutinom 150 mg jedanput na dan.
150 mg once daily.
elvitegravira mora biti 150 mg jedanput na dan.
150 mg once daily.
na dan.
150 mg once every other day
150 mg jedanput svaki drugi dan
150 mg pen Figure A
150 mg brizgalica Slika A
150 mg q12h
150 mg svakih 12 sati
150 mg QD in combination with indinavir
usporedbi kombinacije rifabutina od 150 mg
150 mg simeprevir 12 weeks
150 mg simeprevira 12 tjedana
150 mg suspension for injection
150 mg suspenzija za injekciju
150 mg tablet: yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172) 200 mg tablet: indigo carmine aluminium lake (E132)
150 mg tableta: žuti željezov oksid (E172), crveni željezov oksid (E172), crni željezov oksid (E172) 200 mg tableta: indigo karmin aluminium lake (E132)
150 mg tablets: yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172) 200 mg tablets: indigo carmine aluminium lake (E132)
150 mg tablete: željezov oksid, žuti (E172), željezov oksid, crveni (E172), željezov oksid, crni (E172) 200 mg tablete: indigo karmin aluminium lake (132)
150 mg twice daily
150 mg dva puta dnevno
150 mg twice daily
40 mg jedanput dnevno
150 mg twice daily (N = 93)
300 mg (N=485)
150 mg twice daily vs. warfarin
150 mg dvaput dnevno naspram varfarina
150 mg twice daily when
puta na dan kada se primjenjuje
150 mg twice daily, geometric mean Cmax, AUC(0-) and predose concentration (C) were 1478 ng/ml, 4341 ng*hr/ml and 26 ng/ml, respectively.
Nakon primjene 150 mg dva puta dnevno, geometrijska sredina Cmax, AUC(0--) i koncentracije prije doze (C) bile su 1478 ng/ml, 4341 ng*hr/ml i 26 ng/ml.
150 mg twice weekly on set days is
150 mg triput tjedno preporučuje se
150 mg/2 weeks or 300 mg/4 weeks
150 mg/2 tjedna ili 300 mg/4 tjedna
150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Corbilta dosing should be carefully titrated for optimal clinical response.
150 mg/37,5 mg/200 mg ili 175 mg/43,75 mg/200 mg ili 200 mg/50 mg/200 mg) tabletama, doziranje Corbilte mora biti pažljivo titrirano radi optimalnog kliničkog odgovora.
150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Stalevo dosing should be carefully titrated for optimal clinical response.
150 mg/37,5 mg/200 mg ili 175 mg/43,75 mg/200 mg ili 200 mg/50 mg/200 mg) tabletama, doziranje Staleva mora biti pažljivo titrirano radi optimalnog kliničkog odgovora.
150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg) tablets, Corbilta dosing should be carefully titrated for optimal clinical response.
125 mg/31,25 mg/200 mg ili 150 mg/37,5 mg/200 mg ili 175 mg/43,75 mg/200 mg) tabletama, doziranje Corbilte mora biti pažljivo titrirano radi optimalnog kliničkog odgovora.
150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg) tablets, Stalevo dosing should be carefully titrated for optimal clinical response.
125 mg/31,25 mg/200 mg ili 150 mg/37,5 mg/200 mg ili 175 mg/43,75 mg/200 mg) tabletama, doziranje Staleva mora biti pažljivo titrirano radi optimalnog kliničkog odgovora.
150 mg/4 weeks) to placebo, all three doses of Xeplion were superior to placebo in improving the PANSS total score.
100 mg/4 tjedna ili 150 mg/4 tjedna) uspoređivane s placebom, sve tri doze lijeka Xeplion bile su superiorne placebu u poboljšanju ukupnog rezultata na PANSS ljestvici.
150 mg/ml solution for injection:
Otopina za injekciju od 150 mg/ml
150 micrograms
150 mikrograma
150 micrograms PRE-FILLED SYRINGES LABEL
NALJEPNICA ZA NAPUNJENU ŠTRCALJKU 150 mikrograma